Business Description
Scholar Rock Holding Corp
NAICS : 325412
SIC : 2834
ISIN : US80706P1030
Total Employee Number:
289Description
Scholar Rock Holding Corp is a biopharmaceutical company focused on improving the lives of children and adults with Spinal Muscular Atrophy and other rare, severe, and debilitating neuromuscular diseases. Its pipeline candidates include apitegromab and a subcutaneous formulation of apitegromab. The clinical-stage pipeline also includes SRK-439, an investigational subcutaneously administered fully human anti-pro/latent myostatin antibody with high inhibitory potency and selectivity toward myostatin, being developed for the treatment of rare neuromuscular diseases. The company also maintains early-stage programs focused on therapies for rare, severe, and debilitating neuromuscular diseases.
Financial Strength
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 2.33 | |||||
Equity-to-Asset | 0.52 | |||||
Debt-to-Equity | 0.75 | |||||
Debt-to-EBITDA | -0.52 | |||||
Piotroski F-Score | 1/9 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | -13.5 | |||||
3-Year EPS without NRI Growth Rate | -13.3 | |||||
3-Year FCF Growth Rate | -5.3 | |||||
3-Year Book Growth Rate | -23.4 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 25.86 |
Momentum Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 69.75 | |||||
9-Day RSI | 71.24 | |||||
14-Day RSI | 68.45 | |||||
3-1 Month Momentum % | -7.83 | |||||
6-1 Month Momentum % | 7.53 | |||||
12-1 Month Momentum % | 28.18 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 8.64 | |||||
Quick Ratio | 8.64 | |||||
Cash Ratio | 8.05 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -28 | |||||
Shareholder Yield % | -2.32 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
ROE % | -155.75 | |||||
ROA % | -97.37 | |||||
ROIC % | -1563.4 | |||||
3-Year ROIIC % | 1848 | |||||
ROC (Joel Greenblatt) % | -2861.31 | |||||
ROCE % | -109.43 | |||||
Moat Score | 5 | |||||
Tariff Resilience Score | 7 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PB Ratio | 23.89 | |||||
Price-to-Tangible-Book | 23.84 | |||||
EV-to-EBIT | -15.84 | |||||
EV-to-EBITDA | -15.91 | |||||
EV-to-Forward-Revenue | 836.61 | |||||
EV-to-FCF | -20.92 | |||||
| Price-to-Net-Current-Asset-Value | 25.77 | |||||
| Price-to-Net-Cash | 29.99 | |||||
Earnings Yield (Greenblatt) % | -6.31 | |||||
FCF Yield % | -4.58 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Scholar Rock Holding Corp Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | |||
| EPS (TTM) (€) | -3.087 | ||
| Beta | -2.7334 | ||
| 3-Year Sharpe Ratio | 0.82 | ||
| 3-Year Sortino Ratio | 3.55 | ||
| Volatility % | 61.9 | ||
| 14-Day RSI | 68.45 | ||
| 14-Day ATR (€) | 0.874416 | ||
| 20-Day SMA (€) | 42.8865 | ||
| 12-1 Month Momentum % | 28.18 | ||
| 52-Week Range (€) | 23 - 48 | ||
| Shares Outstanding (Mil) | 119.83 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 1 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Scholar Rock Holding Corp Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Scholar Rock Holding Corp Stock Events
| Event | Date | Price (€) | ||
|---|---|---|---|---|
| Third quarter earnings conference call for 2026 | 2026-11-13 08:00 | In 129 days | ||
| Third quarter earnings results for 2026 | 2026-11-13 | In 128 days | ||
| Second quarter earnings conference call for 2026 | 2026-08-06 08:00 | In 30 days | ||
| Second quarter earnings results for 2026 | 2026-08-06 | In 29 days | ||
| Goldman Sachs 47th Annual Global Healthcare Conference | 2026-06-09 10:00 | 37.97 (+0.00%) | ||
| General meeting for 2026 | 2026-06-04 12:00 | 38.26 (+0.42%) | ||
| Guidance call for 2026 | 2026-06-03 11:40 | 40.26 (+0.00%) | ||
| Guidance call for 2026 | 2026-05-12 11:00 | 40.77 (+0.00%) | ||
| First quarter earnings conference call for 2026 | 2026-05-07 08:00 | 40.38 (+1.08%) | ||
| First quarter earnings results for 2026 | 2026-05-07 | 40.38 (+1.08%) |
Show
Entries
Scholar Rock Holding Corp Frequently Asked Questions
What is Scholar Rock Holding Corp(FRA:2QK)'s stock price today?
The current price of FRA:2QK is €47.68. The 52 week high of FRA:2QK is €48.00 and 52 week low is €23.00.
When is next earnings date of Scholar Rock Holding Corp(FRA:2QK)?
The next earnings date of Scholar Rock Holding Corp(FRA:2QK) is 2026-08-06 Est..
Does Scholar Rock Holding Corp(FRA:2QK) pay dividends? If so, how much?
Scholar Rock Holding Corp(FRA:2QK) does not pay dividend.
Press Release
Articles on Scholar Rock Holding Corp
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers